This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grayburn, P. A. Articles by DeMaria, A. N. Search for Related Content PubMed PubMed Citation Articles by Grayburn, P. A. Articles by DeMaria, A. N.

Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (Albunex) as ultrasound contrast agents in patients with suboptimal echocardiograms

Paul A. Grayburn, MD, FACC^a, James L. Weiss, MD, FACC^*, Terrence C. Hack, MD, FACC, Elizabeth Klodas, MD, FACC^*, Joel S. Raichlen, MD, FACC, Manni A. Vannan, MD, FACC, Allan L. Klein, MD, FACC^||, Dalane W. Kitzman, MD, FACC^¶, Steven G. Chrysant, MD, FACC^#, Jerald L. Cohen, MD, FACC^**, David Abrahamson, MD, FACC, Elyse Foster, MD, FACC, Julio E. Perez, MD, FACC, Gerard P. Aurigemma, MD, FACC^||, Julio A. Panza, MD, FACC^¶, Michael H. Picard, MD, FACC^##, Benjamin F. Byrd, III, MD, FACC^***, Douglas S. Segar, MD, FACC, Stuart A. Jacobson, MD, FACC, David J. Sahn, MD, FACC and Anthony N. DeMaria, MD, FACC^||

^a Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
^* Johns Hopkins University Medical Center, Baltimore, Maryland, USA
Deaconess Nashoba Hospital, Ayer, Massachusetts, USA
Thomas Jefferson University, Philadelphia, Pennsylvania, USA
New England Medical Center, Boston, Massachusetts, USA
^|| Cleveland Clinic Foundation, Cleveland, Ohio, USA
^¶ Bowman Gray Medical Center, Winston-Salem, North Carolina, USA
^# Oklahoma Cardiovascular and Hypotension Center, Oklahoma City, Oklahoma, USA
^** New Jersey Veterans Affairs Medical Center, East Orange, New Jersey, USA
Orange County Heart Institute and Research Center, Orange, California, USA
University of California San Francisco, San Francisco, California, USA
Washington University Medical Center, Saint Louis, Missouri, USA
^|| University of Massachusetts Medical Center, Worchester, Massachusetts, USA
^¶ National Institutes of Health, Bethesda, Maryland, USA
^## Massachusetts General Hospital, Boston, Massachusetts, USA
^*** Vanderbilt University, Nashville, Tennessee, USA
Indiana University, Indianapolis, Indiana, USA
Research for Health, Inc., Houston, Texas, USA
University of Oregon Health Science Center, Portland, Oregon, USA
^|| University of California San Diego, San Diego, California, USA

View larger version (31K): [in a new window]   Figure 1 Percent of patients with full or intermediate LV cavity opacification according to blinded reader A (n = 250), blinded reader B (n = 251) and the investigators (n = 252). Active control is represented by hatched bars; DDFP by open bars. *p < 0.0001 for all comparisons.

View larger version (31K): [in a new window]   Figure 2 Mean LV opacification scores according to blinded readers and investigators. Symbols as in Figure 1. *p < 0.001 for all comparisons.

View larger version (26K): [in a new window]   Figure 3 Change in endocardial border delineation (EBD) scores from baseline according to blinded readers and investigators. Symbols as in Figure 1. *p < 0.001 for all comparisons.

View larger version (121K): [in a new window]   Figure 4 A, Suboptimal baseline echocardiogram showing poor endocardial border definition. Active control did not opacify the LV cavity (not shown). B, Full LV cavity opacification occurs after DDFP, and endocardial borders are clearly seen in all segments.